DOCSLIB.ORG

Lysosomal Storage Disorders

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Lysosomal Storage Disorders Lysosomal Storage Disorders Lysosomal storage diseases are a group of metabolic disorders caused by the lack of key enzymes important for lysosomes to perform their normal function. While clinical trials are underway, there are few approved treatments for lysosomal storage diseases. Current research is focused on finding reliable biomarkers that can be used in these screening programs. Cayman scientists have developed LC-MS/MS assay workflows for quantitative measurement of the activity of certain key enzymes. We also offer a wide range of glycosphingolipid standards associated with the ten main sphingolipidoses that affect the glycosphingolipid pathway. Determination of Lysosomal Acid Lipase Deficiency Lysosomal Acid Lipase Activity MaxSpec® Assay Kit – Item No. 24854 · Easy-to-use reagent kit for the quantification of lysosomal acid lipase activity in dried blood spots · Designed for use in LC-MS-based or fluorometry applications · Includes necessary substrate, product, and internal standard, each provided at known concentrations O O O O LC-MS/MS LAL Activity MaxSpec® Assay Substrate HO O O HO O O 13C Detect LAL 13CH Product and 13C calculate enzyme 13 H2 C activity LAL Activity ® LAL Activity MaxSpec Assay Internal Standard MaxSpec® Assay Product 13 (aka C4-PMHC) Fluorometry Dried Blood Spot Lysosomal Acid Lipase Activity MaxSpec® Assay Kit Workflow Related Products Item No. Product Name Description 16089 4-Methylumbelliferyl Palmitate Fluorogenic substrate for LAL 23891 Lalistat 1 An inhibitor of LAL (IC50 = 68 nM) 25347 Lalistat 2 An inhibitor of LAL (IC50 = 152 nM) 601810 Lysosomal Staining Kit (Red Fluorescence) For imaging of lysosomes in live cells 25152 LysoBrite™ Blue A lysosomal dye 25154 LysoBrite™ Green A lysosomal dye 25157 LysoBrite™ Red A lysosomal dye Learn more at www.caymanchem.com/lysosomalstorage 2019 CAYMAN CHEMICAL · 1180 EAST ELLSWORTH ROAD · ANN ARBOR, MI 48108 · USA · (800) 364-9897 WWW.CAYMANCHEM.COM Sphingolipid Biomarkers Sphingolipidoses (sphingolipid lysosomal storage disorders) result in an accumulation of various sphingolipids in the lysosome. Ten main sphingolipidoses affect the glycosphingolipid pathway: Farber, Krabbe, Gaucher, Metachromatic Leukodystrophy, Fabry, Sandhoff, Niemann-Pick, Sialidosis, Tay-Sachs, and GM1 gangliosidosis. All of these disorders are characterized by an accumulation of sphingolipids in the lysosome due to enzyme deficiency or ineffective transport of lipids from the lysosme. The schematics below detail the enzymes associated with these disorders and the sphingolipid products they produce. NH2 Sphingosine HO C13H27 NH NH OH Sphingosine and Ceramide Accumulation 2 Sphingosine 2 Sphingosine HO C13H27 HO C13H27 OH OH Item No. Product Name Acid Ceramidase O Farber’s Disease O O HO R 9000415 C6 Biotin Ceramide (d18:1/6:0) CH Sphingomyelinase 3 O R R + Acid Ceramidase HO HO H3C N Farber’s Disease Niemann-Pick Disease O P OH 22532 C17 Ceramide (d18:1/17:0) CH3 Types A and B OH Sphingomyelin O O 24396 C18 Ceramide-d3 (d18:1/18:0-d3) O O CH R Ceramide 3 O R HN Ceramide R R HN Ceramide HN HN H C N+ 3 HO C13H27 24428 C18 dihydro Ceramide-d (d18:0/18:0-d ) O P O C13H27 3 3 HO C13H27 HO C13H27 CH3 OH OH OH β-Glucosidase OH OH OH 24464 C18 Ceramide-1-Phosphate-d (d18:1/18:0-d ) HO O 3 3 Gaucher Disease OH HO OH OH OH OH O β-Glucosidase HO O 10007907 Sphingosine (d18:1) OH OH β-Galactosidase HO Gauchers Disease HO Krabbe Disease OH OH O 24371 Sphingosine-d9 (d18:1) O OH HN R O OH OH R Glucosylcerebroside HO O C13H27 HN HO O O Glucosylceramide Accumulation OH OH Galactosylcerebroside O C13H27 HO OH R OH Glucosylcerebroside HN OH O HO O C13H27 Item No. Product Name HO β-Galactosidase OHOH OH OH O Krabbe Disease OH 2- 23206 Glucocerebrosides (buttermilk) HO Arylsulfatase A SO4 OH Metochromatic Leukodystrophy OHOH β-Galactosidase O 23207 Glucocerebrosides (Gaucher’s spleen) OH O O Krabbe Disease HO OHOH OH R OH O HN OH OH R 25850 Glucocerebrosides (soy) O HN Lactosylceramide HO O O C H O HO 13 27 OH O C13H27 OH OH Sulfatide HO3SO OH 24621 C16 Glucosylceramide-d3 (d18:1/16:0-d3) OH O OHOH HO OH R O HN 23208 C6 Biotin Glucosylceramide (d18:1/6:0) AcHN Lactosylceramide O HO O Ganglioside Neuraminidase OH HO O O C13H27 HO OH HO Sialadosis HO2C OH OH 23209 C6 NBD Glucosylceramide (d18:1/6:0) OH O 23213 1-β-D-Glucosylsphingadienine (d18:2 (4E,8E)) OHOH OH R O HN α-Galactosidase A OHOH O O O O 13 O C13H27 Fabry Disease 23212 C Glucosylsphingosine (d18:1) OH HO OH 6 G OH OH HO M3 HO O CO2H OH 23211 1-β-D-Glucosylsphingosine (d18:1) AcHN HO OH OH 24473 N-Glycine Glucosylsphingosine (d18:1) OHOH OHOH Hexosaminidase A O HO OH O Tay-Sachs Disease Gb3 (CTH) NHAc HO O Sandhoff Disease OH OHOH O OH Galactosylceramide Accumulation OH HN R O O O HO O O OH HO O C H OH R O 13 27 Item No. Product Name NHAc O HN HO O OH O O OH OH G O C13H27 M2 OH HO HO OH OH 24471 C6 Galactosylceramide-biotin O CO2H AcHN β-Hexosaminidase A + B 22830 C6 NBD Galactosylceramide (d18:1/6:0) HO OH OHOH OH Sandhoff Disease O HO OH 24466 C15 Galactosylceramide (d18:1/15:0) OHOH NHAc Acid β-Galactosidase O HO OH GM1 Gangliosidosis 22851 C12 NBD Galactosylceramide (d18:1/6:0) OH OH OHOH OH OHOH OHOH O 24467 C18 Galactosylceramide-d (d18:1/18:0-d ) O Gb O 35 35 O O 4 HO O O O OH O HO OH R OH G NHAc O HN NHAc O OH 24322 Galactosylcerebrosides (bovine) M1 OH O OH R O O O C13H27 O HN HO O OH HO O HO O CO H OH OH O C13H27 2 OH HO 20338 Galactosylsphingosine (d18:1) OH OH AcHN HO OH 24620 N-Glycine Galactosylsphingosine (d18:1) OH Lipid Class Enzyme Deficiency Associated Disorder 2019 CAYMAN CHEMICAL · 1180 EAST ELLSWORTH ROAD · ANN ARBOR, MI 48108 · USA · (800) 364-9897 WWW.CAYMANCHEM.COM Gangliosides Accumulation NH2 Sphingosine HO C13H27 NH NH OH 2 Sphingosine 2 Item No. Product Name Sphingosine HO C13H27 HO C13H27 OH OH 24852 Ganglioside G -d D3 3 Acid Ceramidase O O O Farber’s Disease R CH27202 C6 Biotin Ganglioside G (d18:1/6:0) HO 3 O D3 R Sphingomyelinase R Acid Ceramidase HO HO H C N+ Niemann-Pick Disease 3 24840O P OH C6 Biotin Ganglioside G (d18:1/6:0) Farber’s Disease CH M1 Types A and B 3 OH Sphingomyelin 24839 C18 Ganglioside G -d (d18:1/18:0-d ) (ammonium salt) O O M1 3 3 O O CH R Ceramide 3 O R HN Ceramide R R HN Ceramide HN HN 24837 H C N+Lyso-Monosialoganglioside GM1 (ammonium salt) 3 HO C13H27 O P O C13H27 HO C13H27 HO C13H27 CH3 OH OH OH β-Glucosidase OH OH OH 24849 C18 Ganglioside GM2-d3 (d18:1/18:0-d3) (ammonium salt) HO O Gaucher Disease OH HO OH OH OH 24850OH C18 Ganglioside GM3-d3 (d18:1/18:0-d3) (ammonium salt) O β-Glucosidase HO O OH OH β-Galactosidase HO Gauchers Disease HO Krabbe Disease OH OH O Lactosylceramides Accumulation O OH HN R O OH OH ItemR No. Product Name Glucosylcerebroside HO O C13H27 HN HO O O OH OH Galactosylcerebroside O C13H27 HO 16983 Lactosylceramides (bovine brain) OH R OH Glucosylcerebroside HN OH O HO O C13H27 27197 Lactosylceramides (bovine buttermilk) HO β-Galactosidase OHOH OH OH O Krabbe Disease OH 2- HO Arylsulfatase A SO248594 C6 Biotin Lactosylceramide (d18:1/6:0) OH Metochromatic Leukodystrophy OHOH β-Galactosidase O 22828 C6 NBD Lactosylceramide (d18:1/6:0) OH O O Krabbe Disease HO OHOH OH R OH O HN OH OH 22829R C12 NBD Lactosylceramide (d18:1/12:0) O HN Lactosylceramide HO O O C H O HO 13 27 OH O C13H27 OH OH Sulfatide HO3SO 24625 C16 Lactosylceramide-d3 (d18:1/16:0-d3) OH OH O OHOH HO OH R 24868 Lactosylsphingosine (d18:1) O HN AcHN Lactosylceramide O HO O Ganglioside Neuraminidase OH HO O O C13H27 HO 24867 Lactosylsphingosine (d18:1) (synthetic) OH HO Sialadosis HO2C OH OH OH O 24869 N-Glycine Lactosylsphingosine (d18:1) OHOH OH R O HN α-Galactosidase A OHOH O O O O O C13H27 Fabry Disease OH HO Ceramide Trihexosides (Globotriaosylceramides) OH G OH OH HO M3 HO O CO2H Accumulation OH AcHN HO OH OH Item No. Product Name OHOH OHOH Hexosaminidase A O HO OH 24870 Globotriaosylceramides (porcine) O Tay-Sachs Disease Gb3 (CTH) NHAc HO O Sandhoff Disease OH OHOH 24873 Lyso-Globotriaosylceramide (d18:1) O OH OH HN R O O O HO O O OH HO O O C H OH R 24628 C12 NBD Globotriaosylceramide (C18:1/12:0) 13 27 NHAc O HN HO O OH O O OH OH G O C13H27 M2 OH HO OH 24876 C17 Globotriaosylceramide (d18:1/17:0) HO O CO2H OH AcHN 24626 C18 Globotriaosylceramide-d (d18:1/18:0-d ) β-Hexosaminidase A + B HO OH 3 3 OHOH OH Sandhoff Disease O 24874 N-Glycine Globotriaosylsphingosine (d18:1) HO OH OHOH NHAc Acid β-Galactosidase O HO OH GM1 Gangliosidosis OH Globosides (Globotetrahexosylceramides) Accumulation OH OHOH OH OHOH OHOH Item No. Product Name O O Gb O O O 4 HO O O O OH O HO OH R OH G NHAc O HN 24881 Globotetraosylceramides (porcine RBC) NHAc O OH M1 OH O OH R O O O C13H27 O HN HO O OH HO O HO O CO H OH OH O C13H27 2 OH HO OH OH AcHN HO OH OH Lipid Class Enzyme Deficiency Associated Disorder 2019 CAYMAN CHEMICAL · 1180 EAST ELLSWORTH ROAD · ANN ARBOR, MI 48108 · USA · (800) 364-9897 WWW.CAYMANCHEM.COM NH2 Sphingosine HO C13H27 NH NH OH 2 Sphingosine 2 SphingoSphingosylphosphorylcholinesine HOAccumulationC13H27 HO C13H27 OH OH Item No.
Load more

Recommended publications
  • Sphingolipid Metabolism Diseases ⁎ Thomas Kolter, Konrad Sandhoff
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Elsevier - Publisher Connector Biochimica et Biophysica Acta 1758 (2006) 2057–2079 www.elsevier.com/locate/bbamem Review Sphingolipid metabolism diseases ⁎ Thomas Kolter, Konrad Sandhoff Kekulé-Institut für Organische Chemie und Biochemie der Universität, Gerhard-Domagk-Str. 1, D-53121 Bonn, Germany Received 23 December 2005; received in revised form 26 April 2006; accepted 23 May 2006 Available online 14 June 2006 Abstract Human diseases caused by alterations in the metabolism of sphingolipids or glycosphingolipids are mainly disorders of the degradation of these compounds. The sphingolipidoses are a group of monogenic inherited diseases caused by defects in the system of lysosomal sphingolipid degradation, with subsequent accumulation of non-degradable storage material in one or more organs. Most sphingolipidoses are associated with high mortality. Both, the ratio of substrate influx into the lysosomes and the reduced degradative capacity can be addressed by therapeutic approaches. In addition to symptomatic treatments, the current strategies for restoration of the reduced substrate degradation within the lysosome are enzyme replacement therapy (ERT), cell-mediated therapy (CMT) including bone marrow transplantation (BMT) and cell-mediated “cross correction”, gene therapy, and enzyme-enhancement therapy with chemical chaperones. The reduction of substrate influx into the lysosomes can be achieved by substrate reduction therapy. Patients suffering from the attenuated form (type 1) of Gaucher disease and from Fabry disease have been successfully treated with ERT. © 2006 Elsevier B.V. All rights reserved. Keywords: Ceramide; Lysosomal storage disease; Saposin; Sphingolipidose Contents 1. Sphingolipid structure, function and biosynthesis ..........................................2058 1.1.
    [Show full text]
  • The Metabolism of Tay-Sachs Ganglioside: Catabolic Studies with Lysosomal Enzymes from Normal and Tay-Sachs Brain Tissue
    The Metabolism of Tay-Sachs Ganglioside: Catabolic Studies with Lysosomal Enzymes from Normal and Tay-Sachs Brain Tissue JOHN F. TALLMAN, WILLIAM G. JOHNSON, and ROSCOE 0. BRADY From the Developmental and Metabolic Neurology Branch, National Institute of Neurological Diseases and Stroke, National Institutes of Health, Bethesda, Maryland 20014, and the Department of Biochemistry, Georgetown University School of Medicine, Washington, D. C. 20007 A B S T R A C T The catabolism of Tay-Sachs ganglioside, date fronm the 19th century and over 599 cases have been N-acetylgalactosaminyl- (N-acetylneuraminosyl) -galac- reported (1). Onset of the disease is in the first 6 months tosylglucosylceramide, has been studied in lysosomal of life and is characterized by apathy, hyperacusis, motor preparations from normal human brain and brain ob- weakness, and appearance of a macular cherry-red spot tained at biopsy from Tay-Sachs patients. Utilizing Tay- in the retina. Seizures and progressive mental deteriora- Sachs ganglioside labeled with '4C in the N-acetylgalac- tion follow with blindness, deafness, and spasticity, lead- tosaminyl portion or 3H in the N-acetylneuraminosyl ing to a state of decerebrate rigidity. These infants usu- portion, the catabolism of Tay-Sachs ganglioside may be ally die by 3 yr of age (2). initiated by either the removal of the molecule of A change in the chemical composition of the brain of N-acetylgalactosamine or N-acetylneuraminic acid. The such patients was first detected by Klenk who showed activity of the N-acetylgalactosamine-cleaving enzyme that there was an increase in the ganglioside content (hexosaminidase) is drastically diminished in such compared with normal human brain tissue (3).
    [Show full text]
  • Sphingolipids and Cell Signaling: Relationship Between Health and Disease in the Central Nervous System
    Preprints (www.preprints.org) | NOT PEER-REVIEWED | Posted: 6 April 2021 doi:10.20944/preprints202104.0161.v1 Review Sphingolipids and cell signaling: Relationship between health and disease in the central nervous system Andrés Felipe Leal1, Diego A. Suarez1,2, Olga Yaneth Echeverri-Peña1, Sonia Luz Albarracín3, Carlos Javier Alméciga-Díaz1*, Angela Johana Espejo-Mojica1* 1 Institute for the Study of Inborn Errors of Metabolism, Faculty of Science, Pontificia Universidad Javeriana, Bogotá D.C., 110231, Colombia; [email protected] (A.F.L.), [email protected] (D.A.S.), [email protected] (O.Y.E.P.) 2 Faculty of Medicine, Universidad Nacional de Colombia, Bogotá D.C., Colombia; [email protected] (D.A.S.) 3 Nutrition and Biochemistry Department, Faculty of Science, Pontificia Universidad Javeriana, Bogotá D.C., Colombia; [email protected] (S.L.A.) * Correspondence: [email protected]; Tel.: +57-1-3208320 (Ext 4140) (C.J.A-D.). [email protected]; Tel.: +57-1-3208320 (Ext 4099) (A.J.E.M.) Abstract Sphingolipids are lipids derived from an 18-carbons unsaturated amino alcohol, the sphingosine. Ceramide, sphingomyelins, sphingosine-1-phosphates, gangliosides and globosides, are part of this group of lipids that participate in important cellular roles such as structural part of plasmatic and organelle membranes maintaining their function and integrity, cell signaling response, cell growth, cell cycle, cell death, inflammation, cell migration and differentiation, autophagy, angiogenesis, immune system. The metabolism of these lipids involves a broad and complex network of reactions that convert one lipid into others through different specialized enzymes. Impairment of sphingolipids metabolism has been associated with several disorders, from several lysosomal storage diseases, known as sphingolipidoses, to polygenic diseases such as diabetes and Parkinson and Alzheimer diseases.
    [Show full text]
  • GM2 Gangliosidoses: Clinical Features, Pathophysiological Aspects, and Current Therapies
    International Journal of Molecular Sciences Review GM2 Gangliosidoses: Clinical Features, Pathophysiological Aspects, and Current Therapies Andrés Felipe Leal 1 , Eliana Benincore-Flórez 1, Daniela Solano-Galarza 1, Rafael Guillermo Garzón Jaramillo 1 , Olga Yaneth Echeverri-Peña 1, Diego A. Suarez 1,2, Carlos Javier Alméciga-Díaz 1,* and Angela Johana Espejo-Mojica 1,* 1 Institute for the Study of Inborn Errors of Metabolism, Faculty of Science, Pontificia Universidad Javeriana, Bogotá 110231, Colombia; [email protected] (A.F.L.); [email protected] (E.B.-F.); [email protected] (D.S.-G.); [email protected] (R.G.G.J.); [email protected] (O.Y.E.-P.); [email protected] (D.A.S.) 2 Faculty of Medicine, Universidad Nacional de Colombia, Bogotá 110231, Colombia * Correspondence: [email protected] (C.J.A.-D.); [email protected] (A.J.E.-M.); Tel.: +57-1-3208320 (ext. 4140) (C.J.A.-D.); +57-1-3208320 (ext. 4099) (A.J.E.-M.) Received: 6 July 2020; Accepted: 7 August 2020; Published: 27 August 2020 Abstract: GM2 gangliosidoses are a group of pathologies characterized by GM2 ganglioside accumulation into the lysosome due to mutations on the genes encoding for the β-hexosaminidases subunits or the GM2 activator protein. Three GM2 gangliosidoses have been described: Tay–Sachs disease, Sandhoff disease, and the AB variant. Central nervous system dysfunction is the main characteristic of GM2 gangliosidoses patients that include neurodevelopment alterations, neuroinflammation, and neuronal apoptosis. Currently, there is not approved therapy for GM2 gangliosidoses, but different therapeutic strategies have been studied including hematopoietic stem cell transplantation, enzyme replacement therapy, substrate reduction therapy, pharmacological chaperones, and gene therapy.
    [Show full text]
  • Ceramide and Related Molecules in Viral Infections
    International Journal of Molecular Sciences Review Ceramide and Related Molecules in Viral Infections Nadine Beckmann * and Katrin Anne Becker Department of Molecular Biology, University of Duisburg-Essen, 45141 Essen, Germany; [email protected] * Correspondence: [email protected]; Tel.: +49-201-723-1981 Abstract: Ceramide is a lipid messenger at the heart of sphingolipid metabolism. In concert with its metabolizing enzymes, particularly sphingomyelinases, it has key roles in regulating the physical properties of biological membranes, including the formation of membrane microdomains. Thus, ceramide and its related molecules have been attributed significant roles in nearly all steps of the viral life cycle: they may serve directly as receptors or co-receptors for viral entry, form microdomains that cluster entry receptors and/or enable them to adopt the required conformation or regulate their cell surface expression. Sphingolipids can regulate all forms of viral uptake, often through sphingomyelinase activation, and mediate endosomal escape and intracellular trafficking. Ceramide can be key for the formation of viral replication sites. Sphingomyelinases often mediate the release of new virions from infected cells. Moreover, sphingolipids can contribute to viral-induced apoptosis and morbidity in viral diseases, as well as virus immune evasion. Alpha-galactosylceramide, in particular, also plays a significant role in immune modulation in response to viral infections. This review will discuss the roles of ceramide and its related molecules in the different steps of the viral life cycle. We will also discuss how novel strategies could exploit these for therapeutic benefit. Keywords: ceramide; acid sphingomyelinase; sphingolipids; lipid-rafts; α-galactosylceramide; viral Citation: Beckmann, N.; Becker, K.A.
    [Show full text]
  • Hyperglycopeptiduria in Genetic Mucolipidoses
    Tohoku J. exp. Med., 1974, 112, 373-380 Hyperglycopeptiduria in Genetic Mucolipidoses TADAO ORII, TAKAMICHI CHIBA, RYOJI MINAMI, KAZUKO S UKEGAWA and TooRu NAKAO Department of Pediatrics, Sapporo Medical College, Sapporo ORII, T., CHmA, T., MINAMI, R., SUKEUAWA,K. and NAKAO, T. Hyper glycopeptiduria in Genetic Mucolipidoses. Tohoku J. exp. Med., 1974, 112 (4), 373-380 -Urinary cetylpyridinium chloride (CPC)-precipitates and non-CPC- precipitates in normal male children and seven patients with a new type of mucolipidosis, GM1-gangliosidosis type 1, I-cell disease, Hurler syndrome, Morquio syndrome, Gaucher's disease adult type and Tay-Sachs disease were studied using several methods including Sephadex G-25 gel filtration, ECTEOLA-cellulose column chromatography and enzymatic digestion with chondroitinase ABC. 1) Considerable amounts of glycopeptide fractions were detected in the urine of the patients with a new type of mucolipidosis, Gm1-gangliosidosis type 1, I-cell disease and also Gaucher's disease adult type compared with that of normal male children and other patients. 2) The total acid mucopolysaccharides excreted into the urine from two patients with Hurler syndrome and Morquio syndrome were much higher than those excreted in normal male children and other patients. 3) Large amounts of the chondroitinase ABC-resistant acid mucopolysaccharides were found in the urine of patients with Hurler syndrome, Morquio syndrome and Gm,-gangliosidosis type 1. mucolipidoses; glycopeptiduria; Gaucher's disease A group of storage disease which exhibits signs and symptoms of both mucopolysaccharidoses and sphingolipidoses has tentatively been classified as the mucolipidoses by Spranger and Wiedemann (1970). With the exception of the Austin type of sulfatidosis, it has been reported by several workers that the patients with mucolipidosis generally show normal urinary excretion of uronic acid-containing mucopolysaccharides.
    [Show full text]
  • Correction of the Enzymic Defect in Cultured Fibroblasts from Patients with Fabry's Disease: Treatment with Purified A-Galactosidase from Ficin
    Pediat. Res. 7: 684-690 (1973) Fabry's disease genetic disease ficin trihexosylceramide a-galactosidase Correction of the Enzymic Defect in Cultured Fibroblasts from Patients with Fabry's Disease: Treatment with Purified a-Galactosidase from Ficin GLYN DAWSON1341, REUBEN MATALON, AND YU-TEH LI Departments of Pediatrics and Biochemistry, Joseph P. Kennedy, Jr., Mental Retardation Research Center, University of Chicago, Chicago, Illinois, USA Extract Cultured skin fibroblasts from patients with Fabry's disease showed the characteristic a-galactosidase deficiency and accumulated a four- to sixfold excess of trihexosylceram- ide (GL-3). To demonstrate the correction, cells previously labeled with U-14G-glucose were grown in medium containing a purified a-galactosidase preparation obtained from ficin. The results demonstrated that a-galactosidase was taken up rapidly from the medium and that, despite its apparent instability in the fibroblasts, it was able to become incorporated into lysosomes and catabolize the stored trihexosylceramide. These findings support the reports of therapeutic endeavors by renal transplantation and plasma infusion in Fabry's disease and suggest the extension of such studies to other related disorders in which the cultured skin fibroblasts are chemically abnormal, namely, Gaucher's disease, lactosylceramidosis, and GM2-gangliosidosis type II. Speculation It may be possible to replace the specific missing lysosomal hydrolase in various sphingolipidoses and other storage diseases. Although we do not propose to effect enzyme replacement therapy in vivo with a plant enzyme, such studies in tissue culture are valid, and eventually human a-galactosidase, of comparable activity and purity, will become available. Introduction tially unaffected, periodic crises of pain occur and this may be explained by the accumulation of GL-3 in the Fabry's disease (angiokeratoma corporis diffusum uni- dorsal root ganglia [21, 23].
    [Show full text]
  • Mucopolysaccharidoses and Mucolipidoses
    J Clin Pathol: first published as 10.1136/jcp.s3-8.1.64 on 1 January 1974. Downloaded from J. clin. Path., 27, Suppl. (Roy. Coll. Path.), 8, 64-93 Mucopolysaccharidoses and mucolipidoses F. VAN HOOF From the Laboratoire de Chimie Physiologique, Universite Catholique de Louvain, and International Institute of Cellular and Molecular Pathology, Brussels, Belgium Many different syndromes are classified as muco- THE CHEMICAL ERA polysaccharidoses, and, despite remarkable progress Chemical studies, performed mainly by groups in the biochemical understanding of these diseases, working with A. Dorfman, in Chicago and K. much remains to be learned and many cases still Meyer, in New York, have provided most of the escape classification. new knowledge in the field by analysis of tissue and Mucopolysaccharidoses are inborn storage dis- urinary mucopolysaccharides in patients (Dorfman eases, characterized by a complex accumulation of and Lorincz, 1957; Meyer, Grumbach, Linker, and mucopolysaccharides and of glycolipids within the Hoffman, 1958; Meyer, Hoffman, Linker, lysosomes. Sixteen human diseases correspond to Grumbach, and Sampson, 1959). These provided the this definition, of which nine have been presently basis for the subdivision of the 'Hurler syndrome' explained by the deficiency of an acid hydrolase. into six subgroups (McKusick, Kaplan, Wise, They are somewhat arbitrarily divided into muco- Hanley, Suddarth, Sevick, and Maumanee, 1965). polysaccharidoses and mucolipidoses. In muco- The possibility that mucopolysaccharidoses could polysaccharidoses, mucopolysaccharides are the result from an excessive biosynthesis of muco- main storage substances, although an abnormal polysaccharides was suggested by Matalon and accumulation of complex lipids is practically always Dorfman (1966). copyright. disclosed at least by the ultiastructural examination.
    [Show full text]
  • Liposomal Nanovaccine Containing Α-Galactosylceramide and Ganglioside GM3 Stimulates Robust CD8+ T Cell Responses Via CD169+ Macrophages and Cdc1
    Article Liposomal Nanovaccine Containing α-Galactosylceramide and Ganglioside GM3 Stimulates Robust CD8+ T Cell Responses via CD169+ Macrophages and cDC1 Joanna Grabowska 1,†, Dorian A. Stolk 1,† , Maarten K. Nijen Twilhaar 1, Martino Ambrosini 1, Gert Storm 2,3,4, Hans J. van der Vliet 5,6, Tanja D. de Gruijl 5, Yvette van Kooyk 1 and Joke M.M. den Haan 1,* 1 Department of Molecular Cell Biology and Immunology, Amsterdam UMC, Cancer Center Amsterdam, Amsterdam Infection and Immunity Institute, Vrije Universiteit Amsterdam, 1081 HZ Amsterdam, The Netherlands; [email protected] (J.G.); [email protected] (D.A.S.); [email protected] (M.K.N.T.); [email protected] (M.A.); [email protected] (Y.v.K.) 2 Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, 3584 CG Utrecht, The Netherlands; [email protected] 3 Department of Biomaterials Science and Technology, University of Twente, 7500 AE Enschede, The Netherlands 4 Department of Surgery, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 119228, Singapore 5 Department of Medical Oncology, Amsterdam UMC, Cancer Center Amsterdam, Amsterdam Infection and Immunity Institute, Vrije Universiteit Amsterdam, 1081 HV Amsterdam, The Netherlands; [email protected] (H.J.v.d.V.); [email protected] (T.D.d.G.) 6 Lava Therapeutics, 3584 CM Utrecht, The Netherlands * Correspondence: [email protected]; Tel.: +31-20-4448080 Citation: Grabowska, J.; Stolk, D.A.; † Authors contributed equally. Nijen Twilhaar, M.K.; Ambrosini, M.; Storm, G.; van der Vliet, H.J.; Abstract: Successful anti-cancer vaccines aim to prime and reinvigorate cytotoxic T cells and should de Gruijl, T.D.; van Kooyk, Y.; therefore comprise a potent antigen and adjuvant.
    [Show full text]
  • A New Simultaneous Measurement of Lysosphingolipids by LC-MS/MS
    Clin Chem Lab Med 2017; 55(3): 403–414 Open Access Giulia Polo, Alessandro P. Burlina, Thilini B. Kolamunnage, Michele Zampieri, Carlo Dionisi-Vici, Pietro Strisciuglio, Martina Zaninotto, Mario Plebani and Alberto B. Burlina* Diagnosis of sphingolipidoses: a new simultaneous measurement of lysosphingolipids by LC-MS/MS DOI 10.1515/cclm-2016-0340 population. The results demonstrate that the LC-MS/ Received April 21, 2016; accepted July 15, 2016; previously published MS method can quantify different LysoSLs and can be online August 17, 2016 used to identify patients with Fabry (LysoGb3), Gaucher Abstract and Krabbe (HexSph) diseases, prosaposine deficiency (LysoGb3 and HexSph), and Niemann-Pick disease types Background: Lysosphingolipids (LysoSLs) are deriva- A/B and C (LysoSM and LysoSM-509). tives of sphingolipids which have lost the amide-linked Conclusions: This LC-MS/MS method allows a rapid and acyl chain. More recently, LysoSLs have been identi- simultaneous quantification of LysoSLs and is useful as a fied as storage compounds in several sphingolipidoses, biochemical diagnostic tool for sphingolipidoses. including Gaucher, Fabry and Niemann-Pick diseases. To Keywords: Fabry; Gaucher; glucosylsphingosine; Krabbe; date, different methods have been developed to measure LC-MS/MS; LysoGb3; lysosphingolipids; lysosphingomy- each individual lysosphingolipid in plasma. This report elin; Niemann-Pick; psychosine. describes a rapid liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS) assay for simulta- neous quantification of several LysoSLs in plasma. Introduction Methods: We analyzed the following compounds: hexo- sylsphingosine (HexSph), globotriaosylsphingosine Sphingolipidoses are a group of inherited lysosomal storage (LysoGb3), lysosphingomyelin (LysoSM) and lysosphin- disorders (LSD) caused by defects in the lysosomal degrada- gomyelin-509 (LysoSM-509).
    [Show full text]
  • Sphingolipidoses
    J Clin Pathol: first published as 10.1136/jcp.s3-8.1.94 on 1 January 1974. Downloaded from J. clini. Path., 27, Suppl. (Roy. Coll. Path.), 8, 94-105 Sphingolipidoses KONRAD SANDHOFF From the Max-Planck Institute for Psychiatry, Neurochemische Abteilung, Muntich, Gernmany Sphingolipidoses are inborn errors of metabolism, 1882; Sachs, 1896; Fabry, 1898; Anderson, 1898; characterized by the accumulation of sphingo- Alzheimer, 1910; Niemann, 1914; Krabbe, 1916; lipids. These lysosomal diseases (Hers, 1965) are due Scholz, 1925). With progress in the analysis of lipids to a deficiency in the degradative pathway (for these diseases have been more accurately defined as references see Hers and Van Hoof, 1973). So far, specific lipid storage diseases, and it has become neither changes in the extent of sphingolipid bio- feasible to classify them more systematically on the synthesis, ie, an overproduction, nor a deficiency basis of the main accumulating lipid (Aghion, 1934; of a transferase activity have been observed. The Klenk, 1934, 1942; Jatzkewitz, 1958; Svennerholm, latter could result in the absence of the enzyme 1962). However, these nomenclatures, the first product and/or accumulation of its substrates. based on clinical and pathomorphological descrip- Recessive inherited deficiencies of sphingolipid tions and the second based on the main accumulating degrading enzyme activities have been found in all lipid, are not always congruent. For example, tissues that have been tested. The sphingolipid diseases such as infantile GM2-gangliosidosis (Tay- hydrolases studied thus far have been shown to be of Sachs disease) are ganglioside storage diseases, lysosomal origin (for references, see Vaes, 1973). while no ganglioside accumulation has been found Most of these enzymes display an optimal activity in neuronal ceroid-lipofuscinoses (Batten-Vogt dis- in an acidic pH range.
    [Show full text]
  • L-Glucosylceramide: Synthesis, Properties, and Resistance
    Proc. Natl. Acad. Sci. USA Vol. 76, No. 7, pp. 3083-3086, July 1979 Biochemistry L-Glucosylceramide: Synthesis, properties, and resistance to catabolism by glucocerebrosidase in vitro (glucocerebroside/Gaucher disease/animal model/chemical sphingolipidosis) ANDREW E. GAL, PETER G. PENTCHEV, JANICE M. MASSEY, AND ROSCOE 0. BRADY Developmental and Metabolic Neurology Branch, National Institutes of Neurological and Communicative Disorders and Stroke, National Institutes of Health, Bethesda, Maryland 20205 Contributed by Roscoe 0. Brady, March 16, 1979 ABSTRACT Procedures for the synthesis and radioactive activity by the administration of conduritol-3-epoxide to induce labeling of L-glucosylceramide are described. This compound a syndrome resembling Gaucher disease in mice (6). However, is a stereoisomeric analogue of D-glucosylceramide which oc- the quantity of glucosylceramide that accumulated in liver and curs in nature and accumulates in pathological quantity in the 2- to 3-fold than that in normal mice organs and tissues of patients with Gaucher disease. The prop- spleen was only greater erties of L-glucosylceramide that have been examined so far and is therefore far below that found in patients with Gaucher have been found to be indistinguishable from those of the nat- disease (4). In addition, the typical Gaucher bodies or tubular urally occurring glycolipid. However, L-glucosylceramide is structures characteristic of the disorder were not observed in completely refractory to enzymatic hydrolysis by purified pla- spleen, liver, or bone marrow of mice treated with this reagent cental glucocerebrosidase and enzyme(s) present in whole tissue (7). extracts. It is anticipated that L-glucosylceramide will be a disease model at uniquely useful substance for exploring pathogenetic processes Because of the lack of a suitable Gaucher in animal analogues of Gaucher disease.
    [Show full text]